TILT is building a pipeline of innovative cancer immunotherapies targeted at treating solid tumors – ovarian cancer evaluated as the lead indication.
The power of TILT’s approach which enables its proprietary oncolytic viruses to be encoded with a variety of cytokines, means that it should have applicability across a wide range of cancer indications, including ovarian and lung cancer, melanoma, and other solid tumors.
- Product/Program: TILT-123; Ovarian cancer (NCT05271318)
- Indication: Ovarian Cancer (USA and EU)
- Description: Collaboration with Merck & Co (MSD) for the use of pembrolizumab (anti-PD-1)
- Development status: Phase I trials; Rochester (MN, USA), Feinstein (NY, USA), Docrates Cancer Centre (Finland)
- Next milestone(s): 2025: Phase II start
- Product/Program: TILT-123; Melanoma (NCT04217473)
- Indication: Melanoma (EU)
- Description: TILT-123 in combination with TIL therapy
- Development Status: Phase I trials; Herlev (Denmark), Nantes (France)
- Next milestone(s): 2025: Phase Ib start
- Product/Program: TILT-123; Lung cancer (NCT06125197)
- Indication: Lung Cancer (USA)
- Description: Collaboration with Merck MSD for the use of pembrolizumab (anti-PD-1)
- Development status: Phase I trials; Hoag (CA, USA), UCLA (CA, USA)
- Next milestone(s): 2026: Phase I finalized
- Product/Program: TILT-123; Head & neck cancer (NCT05222932)
- Indication: Head and Neck Cancer and Melanoma (USA and EU)
- Description: Collaboration with Merck for the use of avelumab (anti-PD-L1)
- Development status: Phase I trials; New York City (NY, USA), Docrates Cancer Centre (Finland)
- Next milestone(s): 2026: Phase I finalized
- Product/Program: TILT-123; Solid tumors (NCT04695327)
- Indication: Solid Tumors (EU)
- Description: Phase I monotherapy safety for TILT-123
- Development status: Phase I trials; Helsinki University Hospital (Finland), Docrates Cancer Centre (Finland)
- Next milestone(s): 2025: Phase Ib finalized
- Product: TILT-322 Ad5/3 chimeric with next generation payload
- Indication: Solid Tumors
- Description: T-cell recruitment into tumors and local activation. Local delivery of bispecific antibody and cytokine.
- Development status: Pre-clinical
- Product: TILT-234 Ad3
- Indication: Solid tumors
- Description: Enabling technology for Dendritic cell therapy. Available for out-licensing.
- Development status: Pre-clinical
-
TILT-234 structure: Based on Adenovirus serotype 3 (Ad3) genome that is armed with human CD40L.
Science
Our patented TILT® technology, based on oncolytic viral therapies, modifies the tumour microenvironment and eliminates its ability to suppress immune responses to cancer, thereby enhancing T-cell therapies such as checkpoint inhibitors and CAR T-cell therapies.
Partners
Our pioneering approach has been recognized by industry leaders including Germany’s Merck KGaA and MSD (a tradename of Merck & Co., Inc.).